Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

Trial status:Recruiting
Trial ID:
BNT317-01
NCT ID:
NCT06750185
EudraCT ID:
N/A
EU Trial (CTIS) Number:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech SE
Recruiting

Trial Details

This is a first-in-human (FIH), open-label, multiple-site, dose escalation study which will evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of increasing doses of BNT317 in participants with advanced solid tumors.

Medical Condition
  • Solid Tumors
    • Trial Drug
  • BNT317 DL1
    • See more
  • BNT317 DL2
  • BNT317 DL3
  • BNT317 DL4
  • BNT317 DL5 (intermediate)
  • BNT317 DL6 (intermediate)
  • BNT317 DL7 (additional)
    • Phase
    Phase 1
    Type
    Interventional
    Estimated Enrolment
    39
    Estimated Trial Date
    Jan 2025 - Jun 2028

    Trial Participant Requirements

    Age
    18+ years
    Sex
    Female & Male
    Healthy Volunteers
    No
    Inclusion and Exclusion Criteria
    Inclusion criteria
    • Have histologically or cytologically confirmed advanced tumors, who have failed standard therapy, or for whom no standard treatment option is available, or for whom standard therapy is not appropriate.
    • Have at least one measurable lesion based on RECIST 1.1. Lesions treated after prior local treatment (radiotherapy, ablation, interventional procedures, etc.) are generally not considered as target lesions. If the lesion with prior local treatment is the only targeted lesion, evidence-based radiology must be provided to demonstrate disease progression (the single bone metastasis or the single central nervous system [CNS] metastasis should not be considered as a measurable lesion).
    • Adequate hematologic and organ function.
    Exclusion criteria
    • Have received any of the following therapies or drugs within the noted time intervals prior to study treatment:
      • Any prior treatment which inhibits cluster of differentiation 39 (CD39).
      • Vaccination with live attenuated vaccine(s) within 4 weeks prior to the first dose of IMP.
      • Any investigational product within 4 weeks or 5 half lives (if the half life of the other investigational product is known), whichever is longer, before the first dose of IMP in this study or ongoing participation in the active treatment phase of another interventional clinical study.
      • Systemic cytotoxic chemotherapy, immunotherapy within 3 weeks or five half-lives of the chemotherapy (whichever is shorter) prior to the first dose of IMP.
      • Radiation therapy (chest, brain or internal organs) within 4 weeks prior to the first dose of IMP.
      • Palliative radiotherapy to metastasis within 2 weeks prior to the first dose of IMP.
      • Systemic corticosteroids (at a dosage greater than 10 mg/day of prednisone or an equivalent dose of other corticosteroids) within 2 weeks prior to the first dose of IMP. Note: local, intranasal, intraocular, intra-articular or inhaled corticosteroids, short term use (≤7 days) of corticosteroids for prophylaxis (e.g., prevention of contrast agent allergy) or treatment of non-autoimmune conditions (e.g., delayed hypersensitivity reactions caused by exposure to allergens) is allowed.
    • Have any of the following CNS metastases:
      • Untreated brain metastases that are symptomatic or large (e.g., greater than 2 cm).
      • Treated CNS metastases who are not neurologically stable or on steroids or anticonvulsants within 2 weeks before initiating IMP of this study.
      • Brain metastases treated with radiotherapy that are not confirmed stable by magnetic resonance imaging or contrast-enhanced computer tomography 4 weeks after radiotherapy.
      • Participants with known leptomeningeal metastases.
    • Have uncontrolled hypertension or poorly controlled diabetes as specified in the protocol.
    • Have a history of allogeneic hematopoietic stem cell transplantation or organ transplantation.
    • Have a history of serious Grade ≥3 immune-related adverse events (irAEs) or irAEs that led to discontinuation of a prior immunotherapy. Participants with a history of Grade ≥3 irAEs that did not lead to discontinuation of a prior immunotherapy may be included at the discretion of the investigator. If required by the investigator, after consultation with the sponsor.
    • Have uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently).

      • NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

    Trial Locations

    Location
    Status
    Location
    Norton Cancer Institute PARENT
    Louisville, Kentucky, United States, 40202
    Status
    Recruiting
    Location
    START Midwest
    Grand Rapids, Michigan, United States, 49546
    Status
    Recruiting
    Location
    Carolina BioOncology Institute, LLC
    Huntersville, North Carolina, United States, 28078
    Status
    Recruiting
    Location
    Rhode Island Hospital
    East Providence, Rhode Island, United States, 02903
    Status
    Recruiting
    Location
    Mary Crowley Cancer Research
    Dallas, Texas, United States, 75230
    Status
    Recruiting
    Location
    South Texas Accelerated Research Therapeutics (START), LLC
    San Antonio, Texas, United States, 78229
    Status
    Recruiting
    Go to page